Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 1/2012

01-01-2012 | Letter to the Editor

Melanoma in a patient in treatment with eculizumab

Authors: Ausilia Maria Manganoni, Laura Pavoni, Fabio Facchetti, Camillo Farisoglio, Elena Sereni, PierGiacomo Calzavara-Pinton

Published in: Annals of Hematology | Issue 1/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243PubMedCrossRef
2.
Psaty EL, Scope A, Halpern AC, Marghoob AA (2010) Defining the patient at high risk for melanoma. Int J Dermatol 49(4):362–376PubMedCrossRef
3.
Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, Buzaid AC et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206PubMedCrossRef
4.
Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL (2011) Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 32(1):181–182PubMedCrossRef
5.
Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and risk of malignancy: analyses from a large US observational study. Arch Rheum 56:2886–2895CrossRef
6.
Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334–339PubMedCrossRef
Metadata
Title
Melanoma in a patient in treatment with eculizumab
Authors
Ausilia Maria Manganoni
Laura Pavoni
Fabio Facchetti
Camillo Farisoglio
Elena Sereni
PierGiacomo Calzavara-Pinton
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 1/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1229-9

Other articles of this Issue 1/2012

Annals of Hematology 1/2012 Go to the issue

Letter to the Editor

Upfront radioimmunotherapy represents an effective and safe therapeutic option in cutaneous B-cell non-Hodgkin lymphoma

Letter to the Editor

Evans syndrome with cytomegalovirus infection followed by emerging peripheral T-cell lymphoma

Original Article

Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia

Original Article

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

Original Article

Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg

Letter to the Editor

A rare case of supraspinatus tendon rupture

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits